| Epogen (epoetin alfa) / Amgen |
NCT05300477: Pharmacological Countermeasures for High Altitude |
|
|
| Active, not recruiting | 4 | 18 | US | Acetazolamide, Diamox, Erythropoietin, Procrit | United States Army Research Institute of Environmental Medicine, University of Puget Sound | Hypobaric Hypoxia | 09/23 | 03/25 | | |
NCT05078138: Impact of Erythropoietin on Hematological Adaptations and Physical Performance |
|
|
| Completed | 4 | 8 | US | Epoetin Alfa | United States Army Research Institute of Environmental Medicine | Exercise-Induced Anemia, Physical Performance | 04/23 | 04/23 | | |
NCT04134026: Evaluate the Efficacy and Safety of HIF-PHI for the Treatment of Anemia and Risks of Cardiovascular and Cerebrovascular Events in ESRD Newly Initiated Dialysis Patients |
|
|
| Not yet recruiting | 4 | 400 | RoW | HIF-PHI, Epoetin Alfa, Epogen | Second Xiangya Hospital of Central South University | Anemia in Incident Dialysis Patients | 10/23 | 10/24 | | |
EpoAid, NCT06670963: Use of Epoetin Alfa and Iron Derisomaltose in Treatment of Anemia in Patients With Sepsis or Septic Shock: a Randomized Controlled Trial |
|
|
| Recruiting | 4 | 200 | Europe | Iron, EPO, 0.9 % NaCl | Piotr Czempik | Anemia, Sepsis, Septic Shock | 12/26 | 04/27 | | |
| Active, not recruiting | 3 | 247 | US | Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Epoetin Alfa, EPO, Epoetin alfa-epbx, Epogen, Eprex, Procrit, Retacrit, Laboratory Biomarker Analysis, Lenalidomide, CC 5013, CC-5013, CC5013, CDC 501, Revlimid | National Cancer Institute (NCI) | Anemia, Chronic Myelomonocytic Leukemia, De Novo Myelodysplastic Syndrome, Myelodysplastic Syndrome | 07/19 | 10/25 | | |
| Recruiting | 3 | 124 | Europe | EPREX, Epoetin alfa | Groupe Francophone des Myelodysplasies | Myelodysplastic Syndromes | 05/22 | 05/24 | | |
| Completed | 3 | 313 | RoW | Epoetin Alfa, Epogen, Procrit, Normal saline, 0.9% NaCl | University of Sydney, National Health and Medical Research Council, Australia | Hypoxic-Ischemic Encephalopathy | 11/23 | 04/24 | | |
COMMANDS, NCT03682536 / 2017-003190-34: A Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Participants Who Require Red Blood Cell Transfusions and Are ESA Naïve |
|
|
| Active, not recruiting | 3 | 363 | Europe, Canada, Japan, US, RoW | Luspatercept, ACE-536, Epoetin alfa, EPREX®, ERYPO®, PROCRIT® | Celgene, Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA | Myelodysplastic Syndromes | 03/23 | 09/27 | | |
|
|
|
|
| Recruiting | 3 | 2200 | US | Vadadustat, Vafseo, Erythropoiesis Stimulating Agent, Epoetin alfa (EPOGEN), Methoxy polyethylene glycol-epoetin beta (Mircera), or Darbepoetin alfa (Aranesp) | USRC Kidney Research, Akebia Therapeutics | Anemia of Chronic Kidney Disease | 06/26 | 06/26 | | |
ENCASE, NCT06352138: Comparative Study of Two Recombinant Human Erythropoietin Products in Chronic Kidney Disease Patients |
|
|
| Not yet recruiting | 3 | 280 | RoW | Experimental: Epoetin alfa Megalabs® Erythropoietin injectable in intravenous administration., Epoetin alfa Megalabs®, Human recombinant epoetin alfa, Active comparator: European Union licenced epoetin alfa, Epogen®, Human recombinant epoetin alfa | Megalabs, Azidus Laboratories | Anemia of Chronic Kidney Disease | 03/27 | 03/27 | | |
EPO-TRAUMA, NCT04588311: ErythroPOietin Alfa to Prevent Mortality and Reduce Severe Disability in Critically Ill TRAUMA Patients |
|
|
| Recruiting | 3 | 2500 | Europe, RoW | Epoetin Alfa 40000 UNT/ML, Eprex, Binocrit, Sodium Chloride 0.9%, Placebo, Saline | Australian and New Zealand Intensive Care Research Centre, University College Dublin, Medical Research Institute of New Zealand, Medical Research Future Fund, Health Research Board, Ireland, Health Research Council, New Zealand, Irish Critical Care Clinical Trials Network, ANZICS Clinical Trials Group, Monash University | Trauma, Traumatic Injury, Traumatic Brain Injury, Wounds and Injuries, Penetrating Injury, Blunt Injury, Major Trauma, Multiple Trauma | 12/25 | 12/25 | | |
ELEMENT-MDS, NCT05949684: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions |
|
|
| Recruiting | 3 | 360 | Europe, Canada, Japan, US, RoW | Luspatercept, BMS-986346, ACE-536, Reblozyl®, Epoetin Alfa, Epogen®, PROCRIT®, BINOCRIT | Bristol-Myers Squibb | Myelodysplastic Syndromes | 06/27 | 03/30 | | |
ACTRN12613000504718: Dose finding study for Polysialylated Erythropoietin (PSA-EPO) in Chronic Kidney Disease (CKD) subjects |
|
|
| Recruiting | 2 | 90 | | | Xenetic Biosciences PLC, Xenetic Biosciences PLC | Anaemia in Chronic Kidney Disease | | | | |
NCT05265325: A Study of AND017 to Treat Anemia in Chronic Kidney Disease Patients on Dialysis |
|
|
| Completed | 2 | 175 | US, RoW | AND017 capsules TIW, AND017 capsules QW, epoetin alfa, darbepoetin alfa, Mircera®, or their biosimilars | Kind Pharmaceuticals LLC | Renal Anemia | 02/24 | 04/24 | | |
| Active, not recruiting | 1/2 | 17 | US, RoW | Hydroxyurea, Droxia, Hydrea, and hydroxycarbamide., Epoetin Alfa, EPO, epoetin, erythropoietin, erythropoiesis-stimulating agent, ESA, haematopoietin, haemopoietin | Julia Xu, Carnegie Mellon University, American Society of Hematology | Anemia, Sickle Cell, Sickle Cell Disease | 12/24 | 03/25 | | |
NCT00090935: Epoetin Alfa in Treating Cancer-Related Anemia in Patients With Non-Myeloid Cancer Who Are Not Currently Receiving Chemotherapy or Radiation Therapy |
|
|
| Active, not recruiting | N/A | | US | epoetin alfa | Jonsson Comprehensive Cancer Center, National Cancer Institute (NCI) | Anemia, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Precancerous Condition, Unspecified Adult Solid Tumor, Protocol Specific | | | | |
NCT03061565: Long Term Effects of Erythropoietin in Patients With Moderate to Severe Traumatic Brain Injury |
|
|
| Completed | N/A | 356 | RoW | erythropoietin, EPOETIN ALFA, Placebos, Sodium chloride | Australian and New Zealand Intensive Care Research Centre, Monash University | Traumatic Brain Injury | 07/22 | 12/22 | | |
CA056-1083, NCT06581055: A Retrospective Study to Describe Real-World Treatment Patterns and Clinical Outcomes Among Patients With Myelodysplastic Syndromes |
|
|
| Withdrawn | N/A | 86 | RoW | Luspatercept, Epoetin Alfa | Bristol-Myers Squibb | Myelodysplastic Syndromes (MDS) | 03/25 | 03/25 | | |
